Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A
Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, produces and sells pharmaceutical products in China and internationally. The company offers active pharmaceutical ingredients, such as metronidazole, benzoyl metronidazole, dimetrizole, and acyclovir; pharmaceutical intermediates, including imidazole, glyoxylic acid, 2-methyl imidazole, 2-methyl-5-nitroimidazole, … Read more
Market Cap & Net Worth: Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246)
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (SHE:301246) has a market capitalization of $1.15 Billion (CN¥8.40 Billion) as of March 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #10660 globally and #2397 in its home market, demonstrating a 4.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A's stock price CN¥21.01 by its total outstanding shares 400006800 (400.01 Million).
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A Market Cap History: 2023 to 2026
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A's market capitalization history from 2023 to 2026. Data shows change from $1.41 Billion to $1.15 Billion (-20.44% CAGR).
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.42x
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A's market cap is 0.42 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
14.33x
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A's market cap is 14.33 times its annual earnings
10.35x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $1.41 Billion | $2.05 Billion | $87.17 Million | 0.69x | 16.19x |
| 2024 | $737.62 Million | $1.77 Billion | $51.47 Million | 0.42x | 14.33x |
Competitor Companies of 301246 by Market Capitalization
Companies near Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A in the global market cap rankings as of March 18, 2026.
Key companies related to Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A Historical Marketcap From 2023 to 2026
Between 2023 and today, Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A's market cap moved from $1.41 Billion to $ 1.15 Billion, with a yearly change of -20.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.15 Billion | -15.96% |
| 2025 | CN¥1.36 Billion | +84.77% |
| 2024 | CN¥737.62 Million | -47.72% |
| 2023 | CN¥1.41 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.15 Billion USD |
| MoneyControl | $1.15 Billion USD |
| MarketWatch | $1.15 Billion USD |
| marketcap.company | $1.15 Billion USD |
| Reuters | $1.15 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.